Evidence map›Paper›PMID 32055749›Full record

ReviewInvestigative and clinical urology2020

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.

Daniel C Parker, Michael S Cookson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Investigative and clinical urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Celebrating the 60th anniversary ofInvestigative and clinical urology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel C ParkerDepartment of Urology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK, USA.ORCID 0000-0002-4296-8904
Michael S CooksonDepartment of Urology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK, USA.ORCID 0000-0001-8678-0551

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic prostate cancer is a heterogeneous disease entity. Men without prior androgen deprivation therapy exposure are termed metastatic castration sensitive prostate cancer (mCSPC). The goal of this article is to update the reader on the rapidly changing landscape of treatment for men with mCSPC. Along with the options available to the clinician for treatment of men with mCSPC, the care of these patients has evolved into a multi-disciplinary field with expanding roles for medical, urologic, and radiation oncologists.

Indexed as

AndrostenesAntineoplastic AgentsAntineoplastic Agents, HormonalDocetaxelHumansMaleNeoplasm MetastasisProstatic NeoplasmsabirateroneAndrostenesAntineoplastic AgentsAntineoplastic Agents, HormonalDocetaxelClassificationDisease managementDrug therapyProstatic neoplasmsTherapeutics

Identifiers

PMID32055749
PMCPMC7004830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.